What happened
Challenger said Thursday its directors rejected Daiichi Life's raised offer of A$12.20 a share. That price would value the company at around A$8.2 billion, roughly 2% above Wednesday's closing market capitalization. The new proposal was 3.4% higher than the A$11.80 per share approach dismissed last month, but the board still judged it inadequate in the context of handing over control.
Where the bid fits
Headquartered in Tokyo, Daiichi Life aims to purchase the remaining 79.5% stake in Challenger that it does not yet hold. This move comes amid a wave of offers by Japanese insurers aimed at foreign financial firms, a strategy seen as appealing as growth at home is constrained by Japan's shrinking population.
When market news raises questions about value and control, get clarity from the free Market Briefs newsletter today
What it means for your portfolio
Per its website, Challenger - the country's largest annuity provider and a central player in Australia's retirement market - reported managing A$128 billion in assets at the end of March. The bottom line: a modest premium and a higher repeat bid were not enough to sway the board, signaling that any successful control transaction may need to clear a higher bar on valuation.
If you want plain explanations of economic and market developments, sign up for the free Market Briefs and stay informed
